AU2003248356A1 - Beta3-adrenergic receptor agonists - Google Patents

Beta3-adrenergic receptor agonists

Info

Publication number
AU2003248356A1
AU2003248356A1 AU2003248356A AU2003248356A AU2003248356A1 AU 2003248356 A1 AU2003248356 A1 AU 2003248356A1 AU 2003248356 A AU2003248356 A AU 2003248356A AU 2003248356 A AU2003248356 A AU 2003248356A AU 2003248356 A1 AU2003248356 A1 AU 2003248356A1
Authority
AU
Australia
Prior art keywords
beta3
receptor agonists
adrenergic receptor
adrenergic
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003248356A
Other languages
English (en)
Inventor
Jennifer Anne Lafontaine
Bradley Paul Morgan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU2003248356A1 publication Critical patent/AU2003248356A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003248356A 2002-02-27 2003-02-17 Beta3-adrenergic receptor agonists Abandoned AU2003248356A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36025102P 2002-02-27 2002-02-27
US60/360,251 2002-02-27
PCT/IB2003/000590 WO2003072572A1 (fr) 2002-02-27 2003-02-17 Agonistes du recepteur $g(b)3-adrenergique

Publications (1)

Publication Number Publication Date
AU2003248356A1 true AU2003248356A1 (en) 2003-09-09

Family

ID=27766207

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003248356A Abandoned AU2003248356A1 (en) 2002-02-27 2003-02-17 Beta3-adrenergic receptor agonists

Country Status (13)

Country Link
EP (1) EP1485379A1 (fr)
JP (1) JP2005518448A (fr)
AU (1) AU2003248356A1 (fr)
BR (1) BR0308070A (fr)
CA (1) CA2476316A1 (fr)
DO (1) DOP2003000587A (fr)
GT (1) GT200300043A (fr)
MX (1) MXPA04007127A (fr)
PA (1) PA8567701A1 (fr)
PE (1) PE20030943A1 (fr)
TW (1) TW200408637A (fr)
UY (1) UY27680A1 (fr)
WO (1) WO2003072572A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085297A2 (fr) 2001-04-24 2002-10-31 East Carolina University Compositions et formulations contenant un steroide non glucocorticoide et/ou un ubiquinone et kit destines au traitement des maladies respiratoires et pulmonaires
US7405207B2 (en) 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
GB0324654D0 (en) * 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
WO2005061433A2 (fr) * 2003-12-23 2005-07-07 Astellas Pharma Inc. Derives d'amino-alcools
DE102004021779A1 (de) 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP2248524A3 (fr) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Agents preventifs/remedes pour l'incontinence de stress et procede de selecetion de ceux-ci
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
EP2771006B1 (fr) 2011-10-27 2016-05-25 Merck Sharp & Dohme Corp. Procédé pour la fabrication d'agonistes bêta 3 et d'intermédiaires associés
WO2013062881A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Procédé de préparation d'agonistes bêta 3 et d'intermédiaires associés
WO2014150639A1 (fr) 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. Procédé de préparation d'agonistes bêta-3 et d'intermédiaires

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179246C (no) * 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
KR100327273B1 (ko) * 1994-04-08 2002-05-10 고사이 아끼오 에테르화합물,그의용도및그의제조에유용한중간체
MX9708621A (es) * 1995-05-10 1998-02-28 Pfizer AGONISTAS beta-ADRENERGICOS, COMPOSICIONES QUE LOS CONTIENEN Y USO DE LOS MISMOS.
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
SK4612003A3 (en) * 2000-10-20 2004-06-08 Pfizer Prod Inc Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists

Also Published As

Publication number Publication date
WO2003072572A8 (fr) 2004-01-29
GT200300043A (es) 2003-09-22
PE20030943A1 (es) 2003-11-08
CA2476316A1 (fr) 2003-09-04
MXPA04007127A (es) 2005-07-05
EP1485379A1 (fr) 2004-12-15
UY27680A1 (es) 2003-10-31
BR0308070A (pt) 2004-12-21
JP2005518448A (ja) 2005-06-23
WO2003072572A1 (fr) 2003-09-04
DOP2003000587A (es) 2003-08-30
PA8567701A1 (es) 2003-11-12
TW200408637A (en) 2004-06-01

Similar Documents

Publication Publication Date Title
AU2003290700A1 (en) Farnesoid x receptor agonists
AU2003243637A1 (en) Cannabinoid receptor agonists
AU2003233780A1 (en) Novel glucagon antagonists/inverse agonists
AU2003224111A1 (en) Substituted pyrazolo-pyrimidine-4-ones
AU2003231513A1 (en) Pgd2 receptor antagonist
AU2003241836A1 (en) Lpa receptor antagonists
AU2003277576A1 (en) Receptor function controlling agent
AU2003236205A1 (en) Glucagon antagonists/inverse agonists
IL163928A0 (en) Pyridinoylpiperidines as 5-htf agonists
AU2003212708A1 (en) Baculovirus expression system
WO2003072535A8 (fr) Hydroxyethylamines substituees
AU2003238043A1 (en) Substituted imidazotriazines
AU2003245984A1 (en) Hetero-cyclicaly substituted imidazotriazines
AU2003275838A1 (en) Pyrrolidin-2-on derivatives as ep4 receptor agonists
AU2003257032A1 (en) Antibodies against c3a receptor
AU2003303543A1 (en) Agonist antibody against heteroreceptor
AU2002351730A1 (en) Glucagon receptor antagonists/inverse agonists
AU2003294900A1 (en) Substituted 5-aminomethyl-1h-pyrrole-2-carboxamides
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
AU2003277552A1 (en) Receptor regulator
AU2003266342A1 (en) Connecting mechanism
AU2003212366A1 (en) Substituted 4-aminocyclohexanols
AU2003270351A1 (en) Anesthetic-state determining
AU2003244313A1 (en) Androgen receptor agonist
AU2003302405A1 (en) T-cell receptors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase